AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04774029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine induced basivertebral nerve block
Description: Intraosseous lidocaine basivertebral nerve block
Study NCT03563170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK for infusion
Description: NK-92 \[CD16.158V, ER IL-2\]
Study NCT01098305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
Study NCT01098305 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling
Description: All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
Study NCT01098305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
Study NCT05504993 — intervention group
Intervention type: OTHER
Intervention: Frequency of AECOPD
Description: No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
Study NCT03447847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 1 liter of water in meals; 1 liter out of meals
Study NCT01589393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
Study NCT01589393 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
Study NCT00125736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0671
Description: One 50 mg capsule is orally administered three times daily (150 mg/day)
Study NCT00125736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole sodium
Description: One 10mg tablet is administered orally each day
Study NCT00125736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rabeprazole sodium
Description: One 10mg tablet is administered orally each day
Study NCT00125736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E0671 placebo
Description: One 50 mg capsule is orally administered three times daily (150 mg/day)
Study NCT02457130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT02457130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT00224757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoesophageal echocardiography
Description: TEE
Study NCT04427306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-Vec
Description: (talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
Study NCT03956459 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patients with a cancer for which a FDG-PET scanner must be performed
Description: For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:~* Discovery MI~* Discovery IQ~Only one contrast agent injection (FDG) will be given for both scanners.
Study NCT03944096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMT+MTX
Description: FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
Study NCT03944096 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: FMT+MTX
Description: FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
Study NCT04430491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: The high-throughput extraction of large amounts of quantitative image features from medical images
Study NCT01352923 — intervention group
Intervention type: OTHER
Intervention: blood test
Description: preparation of blood platelets
Study NCT01785342 — intervention group
Intervention type: OTHER
Intervention: Biosample and Imaging Collection
Description: Collection of listed biosamples and CT imaging.
Study NCT03287960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Once daily subcutaneous injection
Study NCT03287960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily subcutaneous injection
Study NCT02482727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
Description: A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
Study NCT03391427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: This group will receive lidocaine infusion
Study NCT03391427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: This group will receive Ketamine infusion
Study NCT03391427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine+ketamine
Description: This group will receive mixture of ketamine and lidocaine infusion
Study NCT03391427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: This group will receive saline infusion
Study NCT01099670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Rectal suppository Placebo
Study NCT01099670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04623814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: HEC113995 20mg will be taken orally fasted or with food
Study NCT04623814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC113995
Description: HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
Study NCT03035175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy
Description: Residents intubate using video laryngoscopy.
Study NCT03035175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Laryngoscopy
Description: Residents intubate without using video laryngoscopy.
Study NCT00938743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: 40-80 mg atomoxetine once daily, including titration 10 weeks
Study NCT03475173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSFG-NAVI
Description: laser-speckle blood flow of ocular arteries and veins
Study NCT00545584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
Study NCT04623814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo will be administered fasted or with food for 10 days.
Study NCT00545584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparator: Diet
Description: Diet
Study NCT00545584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparator: Physical Activity
Description: Physical Activity
Study NCT03710395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and breast milk sampling
Description: At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
Study NCT03710395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood and breast milk sampling
Description: At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
Study NCT03710395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
Study NCT03710395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
Study NCT04166721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Immunotherapy
Study NCT01040000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-1C/NEO-102
Description: Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
Study NCT01011959 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN88
Description: This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
Study NCT01689831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
Description: Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
Study NCT01689831 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
Description: Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
Study NCT01689831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reactivity of Aplisol compared to reference standard PPD-S2.
Description: Reference standard PPD-S2 formulated to contain different dose concentrations.
Study NCT01689831 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reactivity of Aplisol compared to reference standard PPD-S2.
Description: Reference standard PPD-S2 formulated to contain different dose concentrations.
Study NCT02714621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)
Study NCT02000674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine : 1mg/kg
Study NCT02000674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium : 1.2 mg/kg
Study NCT02280265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation Factor VIII for injection
Description: Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
Study NCT00302731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol , estriol , progesterone
Study NCT00302731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol, progesterone
Study NCT00302731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estriol, progesterone
Study NCT00302731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: equine estrogens m-progesteroneacetate
Study NCT03054311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Matters
Study NCT02513576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy exercises
Description: Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
Study NCT05375058 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Description: Observational Study; the study did not involve any interventions
Study NCT05921942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg twice daily or 1000 mg once daily
Study NCT01180452 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: enteroscopy
Description: endoscopic enteroscopy to do biopsies on jejunum
Study NCT00943566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
Study NCT00943566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Release Morphine Sulfate
Description: Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
Study NCT02033369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
Study NCT05655130 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: standard of care surgery
Study NCT01194167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
Study NCT01641952 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
Study NCT00527410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 744
Description: Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
Study NCT02547532 — intervention group
Intervention type: OTHER
Intervention: collection of sputum
Study NCT01812564 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Platelet Poor Plasma (PPP)
Study NCT01812564 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma (PRP)
Study NCT02297867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADSCs
Description: autologous ADSCs
Study NCT01569568 — intervention group
Intervention type: OTHER
Intervention: MRI scanning
Description: 1H MRS, DTI, FMRI
Study NCT01569568 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive testing
Description: Behavioral testing
Study NCT01094015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine-prilocaine cream
Description: Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
Study NCT01094015 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gel application for the transmission of ultrasound
Description: 3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix
Study NCT00428233 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Leukemia cell harvest
Description: Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
Study NCT03277066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Active Topical Patch 1
Description: HP-5000 Active Topical Patch 1 were applied on subjects with Osteoarthritis of the knee(s)
Study NCT03277066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Active Topical Patch 2
Description: HP-5000 Active Topical Patch 2 were applied on subjects with Osteoarthritis of the knee(s)
Study NCT03277066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
Study NCT00816712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Testosterone 300 mg, intramuscular injection
Description: Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 300 mg, Intramuscular injection.
Study NCT00816712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Testosterone 100 mg, Intramuscular injection
Description: Day 1 \& 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 100 mg, Intramuscular injection.
Study NCT00816712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo given by Intramuscular Injection
Description: Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Placebo given as intramuscular injection.
Study NCT01639846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10045
Description: RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
Study NCT01639846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for RX-10045 arm
Description: Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
Study NCT04656262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
Study NCT04656262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
Study NCT01880320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD0271 0.3% / CD1579 2.5%
Study NCT02417987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
Study NCT02417987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Volume injection
Description: Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
Study NCT02417987 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: High Volume injection
Description: Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
Study NCT02417987 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous conditioned plasma (ACP)
Description: Injection with 4 mls of ACP around the tendon
Study NCT02417987 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Autologous conditioned plasma (ACP)
Description: Injection with 4 mls of ACP around the tendon
Study NCT03014843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: 20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
Study NCT03014843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone Bromide
Description: 12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
Study NCT03014843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.6 mL of NaCl 0.9% will be injected IM and 1mL bolus injection of NaCl(0.9%) will be administered IV followed by IV NaCl 0.9% infusion
Study NCT04991207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets
Study NCT04991207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Oral Tracleer (bosentan) 125 mg film coated tablets